Shares of Oxford BioMedica (OTCMKTS:OXBDF – Get Free Report) traded up 7.4% on Wednesday. The company traded as high as $6.44 and last traded at $6.44. Approximately 1,000 shares were traded during trading, a decline of 84% from the average daily volume of 6,218 shares. The stock had previously closed at $5.9966.
Analyst Upgrades and Downgrades
Separately, Zacks Research raised Oxford BioMedica to a “hold” rating in a research note on Wednesday, July 22nd. One investment analyst has rated the stock with a Hold rating, According to MarketBeat.com, the stock has an average rating of “Hold”.
Check Out Our Latest Analysis on OXBDF
Oxford BioMedica Stock Performance
Oxford BioMedica Company Profile
Oxford BioMedica plc is a United Kingdom-based contract development and manufacturing organization (CDMO) focused on cell and gene therapies. The company helps biotechnology and pharmaceutical customers develop, test, and manufacture advanced therapies, with expertise in viral-vector technologies used to deliver genetic material into cells.
Its services include process and analytical development, clinical and commercial manufacturing, quality testing, regulatory support, and related research services.
Further Reading
- Five stocks we like better than Oxford BioMedica
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
- Paychex Plunges, Providing the Entry Investors Have Been Waiting For
- The Case for Buying High-Yield General Mills Just Strengthened
- SanDisk’s $1,800 Breakout Turns Memory Hardware Into a Profit Story
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.
